본문으로 건너뛰기
← 뒤로

Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence.

1/5 보강
Cancer imaging : the official publication of the International Cancer Imaging Society 📖 저널 OA 100% 2022: 1/1 OA 2023: 3/3 OA 2024: 5/5 OA 2025: 35/35 OA 2026: 28/28 OA 2022~2026 2025 Vol.25(1) p. 102
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
83 patients with a total of 94 PI-RADS 3+1 lesions in the official clinical report.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
AI potentially benefits more from DCE imaging than experienced prostate radiologists. [CLINICAL TRIAL NUMBER] Not applicable.

Glemser PA, Netzer N, Ziener CH, Wilhelm M, Hielscher T, Zhang KS

📝 환자 설명용 한 줄

[BACKGROUND] According to PI-RADS v2.1, peripheral PI-RADS 3 lesions are upgraded to PI-RADS 4 if dynamic contrast-enhanced MRI is positive (3+1 lesions), however those lesions are radiologically chal

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 2.3-44.3

이 논문을 인용하기

↓ .bib ↓ .ris
APA Glemser PA, Netzer N, et al. (2025). Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence.. Cancer imaging : the official publication of the International Cancer Imaging Society, 25(1), 102. https://doi.org/10.1186/s40644-025-00916-7
MLA Glemser PA, et al.. "Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence.." Cancer imaging : the official publication of the International Cancer Imaging Society, vol. 25, no. 1, 2025, pp. 102.
PMID 40830988 ↗

Abstract

[BACKGROUND] According to PI-RADS v2.1, peripheral PI-RADS 3 lesions are upgraded to PI-RADS 4 if dynamic contrast-enhanced MRI is positive (3+1 lesions), however those lesions are radiologically challenging. We aimed to define criteria by expert consensus and test applicability by other radiologists for sPC prediction of PI-RADS 3+1 lesions and determine their value in integrated regression models.

[METHODS] From consecutive 3 Tesla MR examinations performed between 08/2016 to 12/2018 we identified 85 MRI examinations from 83 patients with a total of 94 PI-RADS 3+1 lesions in the official clinical report. Lesions were retrospectively assessed by expert consensus with construction of a newly devised feature catalogue which was utilized subsequently by two additional radiologists specialized in prostate MRI for independent lesion assessment. With reference to extended fused targeted and systematic TRUS/MRI-biopsy histopathological correlation, relevant catalogue features were identified by univariate analysis and put into context to typically available clinical features and automated AI image assessment utilizing lasso-penalized logistic regression models, also focusing on the contribution of DCE imaging (feature-based, bi- and multiparametric AI-enhanced and solely bi- and multiparametric AI-driven).

[RESULTS] The feature catalog enabled image-based lesional risk stratification for all readers. Expert consensus provided 3 significant features in univariate analysis (adj. p-value <0.05; most relevant feature T2w configuration: "irregular/microlobulated/spiculated", OR 9.0 (95%CI 2.3-44.3); adj. p-value: 0.016). These remained after lasso penalized regression based feature reduction, while the only selected clinical feature was prostate volume (OR<1), enabling nomogram construction. While DCE-derived consensus features did not enhance model performance (bootstrapped AUC), there was a trend for increased performance by including multiparametric AI, but not biparametric AI into models, both for combined and AI-only models.

[CONCLUSIONS] PI-RADS 3+1 lesions can be risk-stratified using lexicon terms and a key feature nomogram. AI potentially benefits more from DCE imaging than experienced prostate radiologists.

[CLINICAL TRIAL NUMBER] Not applicable.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기